Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NAL1279 (lidocaine)
- Development stage
- Preclinical
- Lead developer
- Nal Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Transdermal
01
Overview
NAL1279 is a transdermal patch formulation of lidocaine (4%) being developed by NAL Pharmaceutical Group for over-the-counter (OTC) pain management. As a local anesthetic, lidocaine acts by binding to and blocking voltage-gated sodium channels on the neuronal membrane. This blockade prevents the initiation and conduction of nerve impulses, thereby providing localized analgesic effects. The transdermal delivery system is designed to provide a controlled release of the active ingredient directly to the site of pain, minimizing systemic exposure. The program is currently in the preclinical stage of development.
- Other names
- Lidocaine 4% Patchlidocaine
02
Targets
NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on NAL1279 (lidocaine).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NAL1279 (lidocaine).